CD8A and breast carcinoma: Our findings provide evidence that a Gal-1 blockade using OTX008 treatment successfully promoted antitumor CD8+ T cell responses, thereby sensitizing otherwise refractory breast cancers to anti-PD-1 treatment and attenuating tumor growth and lung metastases.